XW04358Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8

New Technology›Anatomical Regions›Introduction

Billable / Specific Code

ICD-10-PCS XW04358

CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.

XW04358 is a billable ICD-10-PCS procedure code for Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Code Identity

ICD-10-PCS Code

XW04358

Billable Status

Yes — Valid for Submission

Code Describes

Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8

Parent Code

XW0

Short Description

Introduce Mosunetuzumab in Central Vein, Perc, New Tech 8

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

Position	Designation	Value	Meaning
1	Section	X	New Technology
2	Body System	W	Anatomical Regions
3	Operation	0	Introduction
4	BodyPart	4	Central Vein
5	Approach	3	Percutaneous
6	Device/Substance/Technology	5	Mosunetuzumab Antineoplastic
7	Qualifier	8	New Technology Group 8

Code History

Replaces previously assigned code(s):

3E04305 — Introduce Oth Antineoplastic in Central Vein, Perc

Similar Procedure Codes

Filter related codes list:

Questions About XW04358

Is XW04358 a billable code?

Yes. XW04358 is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW04358 mean?

XW04358 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character 5 is the Device/Substance/Technology (Mosunetuzumab Antineoplastic); the 7th character 8 is the Qualifier (New Technology Group 8).